|[September 11, 2013]
Nutra Pharma Provides Update on Inventory and Fulfillment
CORAL SPRINGS, Fla. --(Business Wire)--
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is
developing treatments for Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain,
announced today that they have completed the process of moving their
inventory of their all-natural, non-addictive pain reliever, Nyloxin®,
into their Plantation, Florida facility and that they will be handling
fulfillment services in-house.
"The Distribution and fulfillment of Nyloxin has been a large cost
burden over the last 2 years," commented Rik J Deitsch, CEO of Nutra
Pharma Corporation. "By bringing the product in-house, we will be saving
time on shipments as well as improve our margins by more than 10%," he
continued. "We are completing the process this month of moving over 43
pallets of the Nyloxin product to our existing facility in Plantation,
Florida providing saleable goods at retail as well as wholesale prices
to our customers and Distributors," concluded Mr. Deitsch.
Nyloxin® is a homeopathic drug that utilizes proteins from cobra venom
to relieve pain and inflammation. An analgesic that began gaining U.S.
attention in 1936, cobra venom's effects in minute doses have been shown
by researchers to be superior to that of morphine, a highly addictive
opiate. The product is available in an easy-to-use oral spray for
treating: lower back pain, migraines, neck aches, shoulder pain, cramps
and neuralgia, as well as a topical gel for treating: repetitive stress,
arthritis and joint pain. Nyloxin® is also available in Extra Strength
Additional benefits to Nyloxin® include:
The Company recently announced the delivery of the first order of
Nyloxin® to their newest Distributor, New Vitality (News - Alert). For the past 16
years New Vitality (www.newvitality.com)
has marketed and sold vitamins, health supplements, and personal care
products. Customers learn about their products from advertisements which
use celebrities, sport athletes and doctors to promote them on over 2000
radio and television stations nationwide.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company
specializing in the acquisition, licensing, and commercialization of
pharmaceutical products and technologies for the management of
neurological disorders, cancer, autoimmune, and infectious diseases,
including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV),
Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug
products for sale for the treatment of pain under the brands Cobroxin®
and Nyloxin®. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
SEC (News - Alert) Disclaimer
This press release contains forward-looking statements. The words or
phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially
from those projected in Nutra Pharma's ("the Company") business plan.
The in-house fulfillment of Nyloxin should not be construed as an
indication in any way whatsoever of the future value of the Company's
common stock or its present or future financial condition. The Company's
filings may be accessed at the SEC's Edgar system at www.sec.gov.
Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
Nutra Pharma Corp.
[ InfoTech Spotlight's Homepage ]